EAACI Congress 2025
BackTPS06 - Asthma 01
Friday 13 Jun, 12:00 PM -
13:00 PM Glasgow, United Kingdom
Poster Zone
Thematic Poster Session
D1.91
Baseline characteristics and main clinical outcomes of patients receiving tezepelumab in the framework of use in Special Situations prior to commercialization in Spain (T-ROSS Study)
D1.95
Dupilumab-induced eosinophilia: a transient effect
D1.99
Exploring the relationship between 6 minutes walk test (6MWT) performance and lung function in Severe Asthma and CRSwNP
D1.93
ICS use trajectories in severe asthma patients on benralizumab: real-life data from 3-years follow-up
D1.96
Impact of Dupilumab-induced Eosinophilia on Pulmonary Function Tests and Patient Reported Outcomes Measures (PROMs)
D1.94
Impact of overweight and obesity on clinical remission and Response to Biologics in Severe Asthma Patients
D1.98
MV130 drives the differentiation of human monocytes into dendritic cells with antiallergic properties
D1.102
D1.88
Mepolizumab and intestinal parasitic infection: A case report
D1.90
Remission of asthma on biological therapy: one center experience
D1.92
Results from the EGPAware Delphi study on Red Flags for Suspicion of Eosinophilic Granulomatosis with Polyangiitis (EGPA): current management in Europe
